{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T17:13:49Z","timestamp":1786468429957,"version":"build-2736575974"},"reference-count":73,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":205,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000985","name":"Assisi Foundation of Memphis Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000985","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012524","name":"American Lebanese Syrian Associated Charities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01GM104981"],"award-info":[{"award-number":["R01GM104981"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1RF1NS123174"],"award-info":[{"award-number":["1RF1NS123174"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ymthe.2024.05.029","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T02:33:17Z","timestamp":1716604397000},"page":"2094-2112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["AAV-mediated gene therapy for sialidosis"],"prefix":"10.1016","volume":"32","author":[{"given":"Diantha","family":"van de Vlekkert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Weesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh E.","family":"Fremuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meifen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elida","family":"Gomero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvan","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Sheppard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"d\u2019Azzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.05.029_bib1","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s00018-013-1538-3","article-title":"Lysosomal multienzyme complex: pros and cons of working together","volume":"71","author":"Bonten","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ymthe.2024.05.029_bib2","doi-asserted-by":"crossref","first-page":"28430","DOI":"10.1074\/jbc.M109.031419","article-title":"Heterodimerization of the sialidase NEU1 with the chaperone protective protein\/cathepsin A prevents its premature oligomerization","volume":"284","author":"Bonten","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2024.05.029_bib3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/21678707.2016.1266933","article-title":"Galactosialidosis: historic aspects and overview of investigated and emerging treatment options","volume":"5","author":"Annunziata","year":"2017","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/j.ymthe.2024.05.029_bib4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1517\/21678707.2015.1025746","article-title":"Pathogenesis, Emerging therapeutic targets and Treatment in Sialidosis","volume":"3","author":"d'Azzo","year":"2015","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/j.ymthe.2024.05.029_bib5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ymgme.2019.09.005","article-title":"Type I sialidosis, a normosomatic lysosomal disease, in the differential diagnosis of late-onset ataxia and myoclonus: An overview","volume":"129","author":"Caciotti","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2024.05.029_bib6","first-page":"1911","article-title":"Type II sialidosis: review of the clinical spectrum and identification of a new splicing defect with chitotriosidase assessment in two patients","volume":"256","author":"Caciotti","year":"2009","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.ymthe.2024.05.029_bib7","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/hmg\/11.12.1455","article-title":"Systemic and neurologic abnormalities distinguish the lysosomal disorders sialidosis and galactosialidosis in mice","volume":"11","author":"de Geest","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2024.05.029_bib8","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1046\/j.1462-5822.2000.00071.x","article-title":"Surface-targeted lysosomal membrane glycoprotein-1 (Lamp-1) enhances lysosome exocytosis and cell invasion by Trypanosoma cruzi","volume":"2","author":"Kima","year":"2000","journal-title":"Cell. Microbiol."},{"key":"10.1016\/j.ymthe.2024.05.029_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.642494","article-title":"Lysosomes and Cancer Progression: A Malignant Liaison","volume":"9","author":"Machado","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ymthe.2024.05.029_bib10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.devcel.2008.05.005","article-title":"Neuraminidase 1 is a negative regulator of lysosomal exocytosis","volume":"15","author":"Yogalingam","year":"2008","journal-title":"Dev. Cell"},{"key":"10.1016\/j.ymthe.2024.05.029_bib11","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1038\/ncomms3734","article-title":"Lysosomal NEU1 deficiency affects amyloid precursor protein levels and amyloid-beta secretion via deregulated lysosomal exocytosis","volume":"4","author":"Annunziata","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.05.029_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1500603","article-title":"Regulated lysosomal exocytosis mediates cancer progression","volume":"1","author":"Machado","year":"2015","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2024.05.029_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aav3270","article-title":"Excessive exosome release is the pathogenic pathway linking a lysosomal deficiency to generalized fibrosis","volume":"5","author":"van de Vlekkert","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2024.05.029_bib14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bbadis.2009.10.008","article-title":"Vacuolization and alterations of lysosomal membrane proteins in cochlear marginal cells contribute to hearing loss in neuraminidase 1-deficient mice","volume":"1802","author":"Wu","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymthe.2024.05.029_bib15","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.bbadis.2010.04.002","article-title":"Muscle degeneration in neuraminidase 1-deficient mice results from infiltration of the muscle fibers by expanded connective tissue","volume":"1802","author":"Zanoteli","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymthe.2024.05.029_bib16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ymgme.2005.03.007","article-title":"Short-term, high dose enzyme replacement therapy in sialidosis mice","volume":"85","author":"Wang","year":"2005","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2024.05.029_bib17","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.bbadis.2013.06.002","article-title":"Chaperone-mediated gene therapy with recombinant AAV-PPCA in a new mouse model of type I sialidosis","volume":"1832","author":"Bonten","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymthe.2024.05.029_bib18","article-title":"Conventional and Unconventional Therapeutic Strategies for Sialidosis Type I","volume":"9","author":"Mosca","year":"2020","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.ymthe.2024.05.029_bib19","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/mt.2011.280","article-title":"Self-complementary AAVs induce more potent transgene product-specific immune responses compared to a single-stranded genome","volume":"20","author":"Wu","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.05.029_bib20","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/jimd.12615","article-title":"Advances in therapies for neurological lysosomal storage disorders","volume":"46","author":"Ellison","year":"2023","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2024.05.029_bib21","doi-asserted-by":"crossref","first-page":"13556","DOI":"10.1074\/jbc.RA119.010794","article-title":"Intermittent enzyme replacement therapy with recombinant human beta-galactosidase prevents neuraminidase 1 deficiency","volume":"295","author":"Luu","year":"2020","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2024.05.029_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/cells12050785","article-title":"Various AAV Serotypes and Their Applications in Gene Therapy: An Overview","volume":"12","author":"Issa","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2024.05.029_bib23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nbt1073","article-title":"Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart","volume":"23","author":"Wang","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2024.05.029_bib24","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2024.05.029_bib25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12985-021-01555-7","article-title":"Optimization of AAV vectors to target persistent viral reservoirs","volume":"18","author":"Colon-Thillet","year":"2021","journal-title":"Virol. J."},{"key":"10.1016\/j.ymthe.2024.05.029_bib26","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1016\/j.ymthe.2022.09.015","article-title":"AAV vectors: The Rubik's cube of human gene therapy","volume":"30","author":"Pupo","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.05.029_bib27","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/JVI.76.2.791-801.2002","article-title":"Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity","volume":"76","author":"Rabinowitz","year":"2002","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2024.05.029_bib28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.05.029_bib29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/TACG.S383453","article-title":"Adeno-Associated Virus (AAV) - Based Gene Therapies for Retinal Diseases: Where are We?","volume":"16","author":"Ail","year":"2023","journal-title":"Appl. Clin. Genet."},{"key":"10.1016\/j.ymthe.2024.05.029_bib30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41434-019-0060-0","article-title":"Factors governing the transduction efficiency of adeno-associated virus in the retinal ganglion cells following intravitreal injection","volume":"26","author":"Cao","year":"2019","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2024.05.029_bib31","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1089\/hum.2019.300","article-title":"Different Serotypes of Adeno-Associated Virus Vector- and Lentivirus-Mediated Tropism in Choroid Plexus by Intracerebroventricular Delivery","volume":"31","author":"Chen","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.05.029_bib32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/jimd.12637","article-title":"Liver directed adeno-associated viral vectors to treat metabolic disease","volume":"47","author":"Chuecos","year":"2024","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2024.05.029_bib33","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1089\/hum.2020.043","article-title":"Retinal Tropism and Transduction of Adeno-Associated Virus Varies by Serotype and Route of Delivery (Intravitreal, Subretinal, or Suprachoroidal) in Rats","volume":"31","author":"Han","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.05.029_bib34","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/joim.13308","article-title":"Gene therapy for ischaemic heart disease and heart failure","volume":"290","author":"Korpela","year":"2021","journal-title":"J.\u00a0Intern. Med."},{"key":"10.1016\/j.ymthe.2024.05.029_bib35","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41573-023-00766-7","article-title":"AAV-based in\u00a0vivo gene therapy for neurological disorders","volume":"22","author":"Ling","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2024.05.029_bib36","article-title":"Adeno-Associated Virus (AAV)-Mediated Gene Therapy for Duchenne Muscular Dystrophy: The Issue of Transgene Persistence","volume":"12","author":"Manini","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ymthe.2024.05.029_bib37","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1089\/hum.2022.172","article-title":"Progress in Respiratory Gene Therapy","volume":"33","author":"McLachlan","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.05.029_bib38","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1089\/hum.2019.173","article-title":"Transduction Efficiency of Adeno-Associated Virus Serotypes After Local Injection in Mouse and Human Skeletal Muscle","volume":"31","author":"Muraine","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.05.029_bib39","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.omtm.2021.01.003","article-title":"Gene therapy strategies for idiopathic pulmonary fibrosis: recent advances, current challenges, and future directions","volume":"20","author":"Ruigrok","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.05.029_bib40","article-title":"AAV-mediated gene therapy: Advancing cardiovascular disease treatment","volume":"9","author":"Zhang","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.ymthe.2024.05.029_bib41","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.05.029_bib42","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.05.029_bib43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/archophthalmol.2011.298","article-title":"Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years","volume":"130","author":"Jacobson","year":"2012","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.ymthe.2024.05.029_bib44","doi-asserted-by":"crossref","first-page":"6615","DOI":"10.1128\/JVI.75.14.6615-6624.2001","article-title":"Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors","volume":"75","author":"Halbert","year":"2001","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2024.05.029_bib45","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cardfail.2009.01.013","article-title":"Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1\/2 clinical trial","volume":"15","author":"Jaski","year":"2009","journal-title":"J.\u00a0Card. Fail."},{"key":"10.1016\/j.ymthe.2024.05.029_bib46","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/jgm.686","article-title":"Gene transfer into skeletal muscle using novel AAV serotypes","volume":"7","author":"Louboutin","year":"2005","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.ymthe.2024.05.029_bib47","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jconrel.2023.01.067","article-title":"AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges","volume":"355","author":"Kang","year":"2023","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.ymthe.2024.05.029_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1064924","article-title":"Gene therapy for lysosomal storage diseases: Current clinical trial prospects","volume":"14","author":"Kido","year":"2023","journal-title":"Front. Genet."},{"key":"10.1016\/j.ymthe.2024.05.029_bib49","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current Clinical Applications of In\u00a0Vivo Gene Therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.05.029_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.624988","article-title":"Clinical Trials for Gene Therapy in Lysosomal Diseases With CNS Involvement","volume":"8","author":"Sevin","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ymthe.2024.05.029_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043627","article-title":"Gene Therapy of Sphingolipid Metabolic Disorders","volume":"24","author":"Shaimardanova","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.05.029_bib52","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/emboj\/17.6.1588","article-title":"Transport of human lysosomal neuraminidase to mature lysosomes requires protective protein\/cathepsin A","volume":"17","author":"van der Spoel","year":"1998","journal-title":"EMBO J."},{"key":"10.1016\/j.ymthe.2024.05.029_bib53","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1212\/WNL.0000000000002298","article-title":"Choroid plexus--CSF system: Recent developments and clinical correlations","volume":"86","author":"Benarroch","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2024.05.029_bib54","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1152\/physrev.00060.2021","article-title":"The choroid plexus: a missing link in our understanding of brain development and function","volume":"103","author":"Saunders","year":"2023","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ymthe.2024.05.029_bib55","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cnp.2022.05.004","article-title":"Myoclonus generators in sialidosis","volume":"7","author":"Vial","year":"2022","journal-title":"Clin. Neurophysiol. Pract."},{"key":"10.1016\/j.ymthe.2024.05.029_bib56","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41434-024-00443-3","article-title":"Gene therapy corrects the neurological deficits of mice with sialidosis","volume":"31","author":"Hwu","year":"2024","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2024.05.029_bib57","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/archopht.1983.01040010933017","article-title":"Mucolipidosis I","volume":"101","author":"Cibis","year":"1983","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.ymthe.2024.05.029_bib58","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/archpedi.1981.02130320017006","article-title":"Mucolipidosis I (acid neuraminidase deficiency). Three cases and delineation of the variability of the phenotype","volume":"135","author":"Kelly","year":"1981","journal-title":"Am. J. Dis. Child."},{"key":"10.1016\/j.ymthe.2024.05.029_bib59","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/PL00008412","article-title":"Clinical presentation of congenital sialidosis in a patient with a neuraminidase gene frameshift mutation","volume":"160","author":"Buchholz","year":"2001","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymthe.2024.05.029_bib60","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.5858\/2003-127-1051-PQCADB","article-title":"Pathologic quiz case: a 5-day-old boy with hydrops fetalis. Mucolipidoses I (Sialidosis III)","volume":"127","author":"Godra","year":"2003","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.ymthe.2024.05.029_bib61","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.braindev.2013.01.012","article-title":"Histological, biochemical, and genetic characterization of early-onset fulminating sialidosis type 2 in a Korean neonate with hydrops fetalis","volume":"36","author":"Lee","year":"2014","journal-title":"Brain Dev."},{"key":"10.1016\/j.ymthe.2024.05.029_bib62","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1017\/S1047951120004953","article-title":"Cardiovascular involvement in alpha-n-acetyl neuraminidase deficiency syndromes (sialidosis type I and II)","volume":"31","author":"Prasanna","year":"2021","journal-title":"Cardiol. Young"},{"key":"10.1016\/j.ymthe.2024.05.029_bib63","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0887-8994(88)90032-X","article-title":"Infantile sialic acid storage disease associated with renal disease","volume":"4","author":"Pueschel","year":"1988","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ymthe.2024.05.029_bib64","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/ajmg.a.10710","article-title":"Clinical variability of type II sialidosis by C808T mutation","volume":"116A","author":"Rodriguez Criado","year":"2003","journal-title":"Am. J. Med. Genet. A."},{"key":"10.1016\/j.ymthe.2024.05.029_bib65","first-page":"1048","article-title":"Novel mutations in the neuraminidase-1 (NEU1) gene in two patients of sialidosis in India","volume":"136","author":"Ranganath","year":"2012","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.ymthe.2024.05.029_bib66","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1038\/s41467-019-11568-0","article-title":"MYC competes with MiT\/TFE in regulating lysosomal biogenesis and autophagy through an epigenetic rheostat","volume":"10","author":"Annunziata","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.05.029_bib67","doi-asserted-by":"crossref","DOI":"10.1038\/srep37583","article-title":"Identification of Small Molecule Compounds for Pharmacological Chaperone Therapy of Aspartylglucosaminuria","volume":"6","author":"Banning","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2024.05.029_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci10080506","article-title":"Diagnosis and Management of Type 1 Sialidosis: Clinical Insights from Long-Term Care of Four Unrelated Patients","volume":"10","author":"Coppola","year":"2020","journal-title":"Brain Sci."},{"key":"10.1016\/j.ymthe.2024.05.029_bib69","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ebcr.2018.02.005","article-title":"Seizure remission and improvement of neurological function in sialidosis with perampanel therapy","volume":"10","author":"Hu","year":"2018","journal-title":"Epilepsy Behav. Case Rep."},{"key":"10.1016\/j.ymthe.2024.05.029_bib70","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.omtm.2021.10.007","article-title":"AAV-mediated gene therapy for galactosialidosis: A long-term safety and efficacy study","volume":"23","author":"Hu","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.05.029_bib71","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1089\/hum.2010.202","article-title":"Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial","volume":"22","author":"Allay","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.05.029_bib72","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.omtm.2020.11.012","article-title":"Galactosialidosis: preclinical enzyme replacement therapy in a mouse model of the disease, a proof of concept","volume":"20","author":"Cadaoas","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.05.029_bib73","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3389\/fphar.2020.00142","article-title":"Cross-Talk Between Extracellular Matrix and Skeletal Muscle: Implications for Myopathies","volume":"11","author":"Ahmad","year":"2020","journal-title":"Front. Pharmacol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624003319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624003319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T14:59:33Z","timestamp":1740236373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624003319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":73,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1525001624003319"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.05.029","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.11.10.566667","asserted-by":"object"}]},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AAV-mediated gene therapy for sialidosis","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.05.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}